In re: Bayer Corporation Combination Aspirin Products Marketing and Sales Practices Litigation
As a result of the Center’s objection, the parties modified the settlement to increase direct payments to the class by over $5.8M. Our second objection resulted in a third-party recipient of settlement funds that better suited the purpose of the litigation.